20:00 , Apr 27, 2018 |  BC Week In Review  |  Clinical News

CFDA approves Canbridge's oral mucositis drug

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved Caphosol (CAN002) to treat oral mucositis. The company has Chinese rights to the supersaturated calcium phosphate rinse from EUSA Pharma Ltd. (Hemel Hempstead, U.K.). The company...
12:03 , Apr 26, 2018 |  BC Extra  |  Company News

CFDA approves Canbridge's oral mucositis drug

Canbridge Life Sciences Ltd. (Beijing, China) said China FDA approved Caphosol (CAN002) to treat oral mucositis. The company has Chinese rights to the supersaturated calcium phosphate rinse from EUSA Pharma Ltd. (Hemel Hempstead, U.K.). The company...
07:00 , Mar 28, 2016 |  BioCentury  |  Strategy

Canbridge can-can

Canbridge Life Sciences Ltd.'s deal with Aveo Pharmaceuticals Inc. will see the Chinese biotech developing its first programs outside Asia. But Chairman and CEO James Xue says the company is not deviating from its strategy,...
07:00 , Apr 13, 2015 |  BC Week In Review  |  Company News

EUSA Pharma, Jazz Pharmaceuticals deal

Essex Bidco Ltd. acquired five approved specialty hospital products and related commercial infrastructure from Jazz for about $33 million in cash. Jazz gained rights to the products under its 2012 acquisition of EUSA Pharma...
08:00 , Dec 8, 2014 |  BioCentury  |  Finance

Fast funding for Chinese healthcare innovators

TF Capital plans to invest its inaugural China-focused VC fund in innovation and technology in that nation's healthcare space. The firm, which has about $50 million to invest, has already made about eight investments, including...
02:50 , Dec 3, 2014 |  BC Extra  |  Financial News

Canbridge raises $10M in series A

Canbridge Life Sciences Ltd. (Beijing, China) raised $10 million in a series A round from Qiming Venture Partners and TF Capital. Canbridge in-licenses compounds from small biotechs in the U.S. and Europe to develop in...
07:00 , May 7, 2012 |  BioCentury  |  Strategy

Jazz's big band sound

A 2008 decision to concentrate on its commercial business has paid off for Jazz Pharmaceuticals Inc. The company has quadrupled its revenues, reduced its debt and increased its number of marketed drugs tenfold with two...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Company News

EUSA, Jazz Pharmaceuticals deal

Jazz will acquire cancer-focused specialty pharma EUSA for $650 million in cash, plus a potential $50 million payment tied to 2013 U.S. sales of EUSA's Erwinaze. Jazz, which had 2011 revenue of $272.3 million,...
01:02 , Apr 27, 2012 |  BC Extra  |  Top Story

Jazz tunes into cancer with EUSA buy

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) will acquire cancer-focused specialty pharma EUSA Pharma Inc. (Langhorne, Pa.) for $650 million in cash, plus a potential $50 million payment tied to 2013 U.S. sales of EUSA's Erwinaze. Jazz, which...
07:00 , Apr 6, 2009 |  BC Week In Review  |  Company News

EUSA sales and marketing update

EUSA launched Caphosol in Europe to treat and prevent oral mucositis caused by chemotherapy and to treat hyposalivation and xerostomia (dry mouth). The supersaturated calcium phosphate rinse has been available in the U.S. since 2007....